Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study in healthy adults of the safety, tolerability, and immunogenicity of recombinant hepatitis B vaccine manufactured with a modified process.

Next Previous
X
Search
Trial Profile

A study in healthy adults of the safety, tolerability, and immunogenicity of recombinant hepatitis B vaccine manufactured with a modified process.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hepatitis B vaccine recombinant (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics; Registrational
  • Sponsors Merck & Co; Merck Sharp & Dohme

    • Most Recent Events

    • 29 Oct 2009 Results were presented at IDSA 2009.
    • 08 Apr 2009 Additional trial identifier V232-059 identified as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Actual start date changed from Mar 2007 to Nov 2006 as reported by Clinicaltrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top